Bausch Health Companies Inc. Aktie News

LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025. A live audio webcast of the event will be accessible on the Investor ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at the New York Stock Exchange. Leading Through Reinvention Over the past few years, Bausch + Lomb has undergone a complete transformation by red...

Bausch Health (BHC) delivered a strong Q3, exceeding expectations and reinforcing the medium-term deleveraging investment thesis. BHC's upside potential is now 36.8%, with a Buy rating maintained and a fair value target of $9.1 per share (range $8-10). The core thesis centers on debt reduction, but significant risks remain, especially Xifaxan sales declines and refinancing challenges in 2027-2028.

Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company, and OraPharma, its dental products business, today announced the commercial expansion of OraPhar...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on Thursday, Nov. 13, 2025, at the New York Stock Exchange. Chairman and CEO Brent Saunders will provide an update on the company's transformation and strategic outlook, and Executive Vice President an...

Bausch Health Companies delivered strong Q3 results, with revenue up 6.8% year-over-year and EPS beating estimates by $0.10. BHC's growth is driven by successful product launches like Cabtreo, robust Xifaxan performance, and expansion in dermatology and aesthetics segments. The company raised guidance on adjusted EBITDA and operating cash flow, supported by cost management and strategic investm...

Bausch Health Companies Inc. ( BHC ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Garen Sarafian - VP & Head of Investor Relations Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Chi Meng Fong - BofA Securities, Research Division Liwen Wang - Jefferies LLC...

Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 million Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 million acquired In-Process Research & Developme...